AVX-001

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H29F3OS
Molecular Weight	386.515
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	5
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC\C=C/C\C=C/C\C=C/C\C=C/CC\C=C\CSCC(=O)C(F)(F)F

InChI

InChIKey=RBPYIYOPSGHFQG-IIFHDYRKSA-N

InChI=1S/C21H29F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-20(25)21(22,23)24/h3-4,6-7,9-10,12-13,16-17H,2,5,8,11,14-15,18-19H2,1H3/b4-3-,7-6-,10-9-,13-12-,17-16+

HIDE SMILES / InChI

Molecular Formula	C21H29F3OS
Molecular Weight	386.515
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	5
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:40:26 GMT 2023` Edited by `admin` on `Sat Dec 16 11:40:26 GMT 2023`
Record UNII	G8333V26KK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AVX-001

Code

English

AKH-217

Code

English

AVX001

Code

English

1,1,1-TRIFLUORO-3-(((2E,6Z,9Z,12Z,15Z)-OCTADECA-2,6,9,12,15-PENTAEN-1-YL)THIO)PROPAN-2-ONE

Systematic Name

English

2-PROPANONE, 1,1,1-TRIFLUORO-3-((2E,6Z,9Z,12Z,15Z)-2,6,9,12,15-OCTADECAPENTAENYLTHIO)-

Systematic Name

English

1-((2E,6Z,9Z,12Z,15Z)-OCTADECA-3,6,9,12,15-PENTAEN-1-THIO)-3,3,3-TRIFLUOROACETONE

Systematic Name

English

AKH217

Code

English

Code System Code Type Description

PUBCHEM

10309482

Created by admin on Sat Dec 16 11:40:27 GMT 2023 , Edited by admin on Sat Dec 16 11:40:27 GMT 2023

PRIMARY

FDA UNII

G8333V26KK

Created by admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023

PRIMARY

SMS_ID

300000033557

Created by admin on Sat Dec 16 11:40:27 GMT 2023 , Edited by admin on Sat Dec 16 11:40:27 GMT 2023

PRIMARY

CAS

300553-18-8

Created by admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023

PRIMARY

Related Record Type Details


					G8333V26KK

AVX-001

ACTIVE MOIETY

Comments:

Originator: Avexxin; Class: Antipsoriatic, Small molecule; Mechanism of Action: Immunomodulator, Phospholipase A2 modulator, Tumour necrosis factor inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phase: Phase II Plaque psoriasis; Most Recent Events: 02 Jul 2015 Avexxin completes a phase-I/II trial in Psoriasis, 01 May 2015 Avexxin completes a phase II trial in Plaque psoriasis in Denmark (EudraCT2014-004467-20), 10 Dec 2014 Phase-II clinical trials in Plaque psoriasis in Denmark (Topical) (EudraCT2014-004467-20)